Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Post by Ryeman40on Jan 18, 2021 11:06am
255 Views
Post# 32319650

Manipulated

Manipulated

Another small canadian cap Sernova had positive preliminary safety and efficacy in their phase 1/2 trial. They are trading at around 383 million market cap with about 200 million shares outstanding. 

Maybe Antibe is being held down. I was in a company this summer called Avinger bought in around .40. They had a medical instrument approved by fda which plunged the stock into the .20's. Huh? There it sat until the end of December. The company had until May 2021 to get stock price back to $1 but they wanted a reverse split which would of been the 3rd in 2 years. Shareholders voted no TWICE! to a reverse split so the company didn't and magically the price started going back up past $1. Good for me bad for people who panicked and sold. Manipulated. 

They'll let this go when they want to just have to be patient. If you can time the lowest and the highest of the stock price good for you but i just buy and hold and usually works out. Pretty soon we'll be wondering why we didn't buy more. 

<< Previous
Bullboard Posts
Next >>